These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 35391713)

  • 21. Direct degradation and stabilization of proteins: New horizons in treatment of nonalcoholic steatohepatitis.
    Wang Y; Zheng J; Long Y; Wu W; Zhu Y
    Biochem Pharmacol; 2024 Feb; 220():115989. PubMed ID: 38122854
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resmetirom, the long-awaited first treatment for metabolic dysfunction-associated steatohepatitis and liver fibrosis?
    Vidal-Cevallos P; Chávez-Tapia N
    Med; 2024 May; 5(5):375-376. PubMed ID: 38733968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The metabolic basis of nonalcoholic steatohepatitis.
    Chakravarthy MV; Neuschwander-Tetri BA
    Endocrinol Diabetes Metab; 2020 Oct; 3(4):e00112. PubMed ID: 33102794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Innovative Molecular Targets and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 3.0.
    Vairetti M; Colucci G; Ferrigno A
    Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indigenous wisdom of a Kwatha to treat NASH: An insight into the mechanism.
    Yellurkar ML; Prasanna VS; Das P; Sarkar S; Matta R; Dhaked DK; Peraman R; Taraphdar AK; Nanjappan SK; Velayutham R; Arumugam S
    J Ethnopharmacol; 2024 May; 326():117935. PubMed ID: 38408692
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oily fish, coffee and walnuts: Dietary treatment for nonalcoholic fatty liver disease.
    Gupta V; Mah XJ; Garcia MC; Antonypillai C; van der Poorten D
    World J Gastroenterol; 2015 Oct; 21(37):10621-35. PubMed ID: 26457022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. N
    Luo P; Li S; Jing W; Tu J; Long X
    Trends Endocrinol Metab; 2023 Dec; 34(12):838-848. PubMed ID: 37758602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Linking nutrient sensing, mitochondrial function, and PRR immune cell signaling in liver disease.
    Kemper C; Sack MN
    Trends Immunol; 2022 Nov; 43(11):886-900. PubMed ID: 36216719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Future therapeutic perspectives in nonalcoholic fatty liver disease: a focus on nuclear receptors, a promising therapeutic target.
    Stan SI; Biciuşcă V; Clenciu D; Mitrea A; Boldeanu MV; Durand P; Dănoiu S
    Med Pharm Rep; 2024 Apr; 97(2):111-119. PubMed ID: 38746033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inflammatory liver diseases and susceptibility to sepsis.
    Lu H
    Clin Sci (Lond); 2024 Apr; 138(7):435-487. PubMed ID: 38571396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Matrix Gla Protein, a New Target Fighting Against Fibrosis of Nonalcoholic Steatohepatitis?
    Hinz K; Ding WX
    Cell Mol Gastroenterol Hepatol; 2023; 16(6):1034-1035. PubMed ID: 37839467
    [No Abstract]   [Full Text] [Related]  

  • 32. γδT Cells and CD1d, Novel Immune Players in Alcoholic and Nonalcoholic Steatohepatitis?
    Wang X; Gao B
    Hepatology; 2020 Feb; 71(2):408-410. PubMed ID: 31698503
    [No Abstract]   [Full Text] [Related]  

  • 33. The Hepatic Sinusoid in Aging and Disease: Update and Advances From the 20th Liver Sinusoid Meeting.
    Ortega-Ribera M; Hunt NJ; Gracia-Sancho J; Cogger VC
    Hepatol Commun; 2020 Jul; 4(7):1087-1098. PubMed ID: 32626839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natural products in pursuing novel therapies of nonalcoholic fatty liver disease and steatohepatitis.
    Li H; Guan T; Qin S; Xu Q; Yin L; Hu Q
    Drug Discov Today; 2023 Mar; 28(3):103471. PubMed ID: 36610488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD).
    Subramanian P; Hampe J; Tacke F; Chavakis T
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dimethyloxalylglycine Suppresses SREBP1c and Lipogenic Gene Expressions in Hepatocytes Independently of HIF1A.
    Kwon YS; Cho YE; Kim Y; Koh M; Hwang S
    Curr Issues Mol Biol; 2024 Mar; 46(3):2386-2397. PubMed ID: 38534767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives.
    Clayton-Chubb D; Kemp W; Majeed A; Lubel JS; Hodge A; Roberts SK
    Nutrients; 2023 Jan; 15(3):. PubMed ID: 36771394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune-related pathogenesis and therapeutic strategies of nonalcoholic steatohepatitis.
    Chung KW; Cho YE; Kim SJ; Hwang S
    Arch Pharm Res; 2022 Apr; 45(4):229-244. PubMed ID: 35391713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
    Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
    Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.